Drug intelligence / Profile preview

CNS10-NPC-GDNF

Development stage: Phase 1
Lead developer: Cedars-Sinai
Modality: Cell Therapies, Gene Therapies
Administration: Intracerebral

Overview

CNS10-NPC-GDNF is a combined cell and gene therapy that involves transplanting neural progenitor cells genetically engineered to produce glial cell line-derived neurotrophic factor (GDNF) into the motor cortex of patients with amyotrophic lateral sclerosis (ALS). GDNF is a protein that promotes the survival of neural cells. The therapy aims to protect motor neurons and improve the quality of life for ALS patients.

Other names: Human Neural Progenitor Cells Secreting Glial Cell Line-Derived Neurotrophic Factor

Targets

GFRA1 (Glial cell line-derived neurotrophic factor family receptor alpha 1)

Beyond the preview

Go deeper on CNS10-NPC-GDNF.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CNS10-NPC-GDNF.

Explore the full profile